Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News ProStrakan notes growth in interim management statement

ProStrakan notes growth in interim management statement

16th November 2010

ProStrakan has published its interim management statement for the first ten months of 2010, during which the company experienced double-digit year-on-year growth.

The Scotland-based pharmaceutical company's total revenues for January to October 2010 came to 76.8 million pounds, up by 20 percent on the same period of 2009, thanks to increased product sales in the EU and US.

Offerings such as Rectogesic, Tostran and Xomolix all saw sales improvements in 2010, as did the UK-exclusive Adcal-D3, while the firm's revenues from Abstral jumped by 345 percent compared to 2009.

In addition, the company expects to receive US Food and Drug Administration approval for Abstral soon, as well as for Fortesta, which will be sold in America by ProStrakan's partner Endo Pharmaceuticals.

Peter Allen, chairman and acting chief executive of ProStrakan, added: "The last few months have been interesting and challenging."

Mr Allen has occupied the top role at ProStrakan since the departure of Dr Wilson Totten from the company in September 2010.ADNFCR-8000103-ID-800237771-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.